Showing results (21-30 of 180) with videos related to
Sort By:
Pageof 18
Autoimmunity Reviews|May 31, 2011
Immune-mediated CNS diseases: a review on nosological classification and clinical featuresUwe K Zettl, Olaf Stüve, Robert PatejdlEuropean Neurology|February 15, 2014
Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticityPeter Flachenecker, Thomas Henze, Uwe K ZettlPlos One|August 14, 2013
Headaches in multiple sclerosis patients might imply an inflammatorial processJan Möhrke, Peter Kropp, Uwe K ZettlEuropean Neurology|June 20, 2014
Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practicePeter Flachenecker, Thomas Henze, Uwe K ZettlJournal of Neurology|May 16, 2007
Coping with neuroimmunological diseasesThomas Klauer, Wolfgang Schneider, Uwe K ZettlJournal of Immunology (Baltimore, Md. : 1950)|April 10, 2019
Dysregulation of Inflammasome Priming and Activation by MicroRNAs in Human Immune-Mediated DiseasesNina Boxberger, Michael Hecker, Uwe K ZettlEuropean Neurology|October 8, 2003
Therapy with intravenous immunoglobulins: complications and side-effectsMatthias Wittstock, Reiner Benecke, Uwe K ZettlEuropean Neurology|January 25, 2017
The Development of Sayk's Cell Sedimentation Chamber: A Historical View on Clinical Cerebrospinal Fluid DiagnosticsNathalie Dahlmann, Uwe K Zettl, Ekkehardt KumbierCurrent Pharmaceutical Design|May 23, 2012
Monoclonal antibodies in the treatment of neuroimmunological diseasesPaulus S Rommer, Robert Patejdl, Uwe K ZettlCurrent Pharmaceutical Design|May 23, 2012
Management of spasticity in progressive multiple sclerosis: efficacy of repeated intrathecal triamcinolone acetonide administrationMazen Abu-Mugheisib, Reiner Benecke, Uwe K ZettlPageof 18